BackNautilus Biotechnology Overview

Nautilus Biotechnology Receivables

Track Nautilus Biotechnology's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Nautilus Biotechnology Receivables History

Loading

Nautilus Biotechnology vs. peers: Receivables Comparison

Loading

Nautilus Biotechnology Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Nautilus Biotechnology (NAUT) FAQ

As of the most recent data (June 2026), NAUT shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NAUT's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Nautilus Biotechnology is outperforming or lagging.

Tracking NAUT's receivables over time shows whether Nautilus Biotechnology is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Nautilus Biotechnology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Nautilus Biotechnology's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.